STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Karo Bio (STP:KARO):
The anti-diabetic compound KB3305 has now entered phase I clinical studies. Single ascending doses as well as multiple ascending doses will be given to healthy volunteers as well as to type 2 diabetes patients, to evaluate safety, tolerability and pharmacodynamic parameters such as fasting and postprandial blood glucose lowering efficacy. The entire phase I program will include about 110 subjects.
